We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+6.32%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$16.2B
AUM Growth
+$1.75B
Cap. Flow
+$1.1B
Cap. Flow %
6.8%
Top 10 Hldgs %
54.17%
Holding
115
New
28
Increased
36
Reduced
22
Closed
20

Top Buys

Rank Stock Value
1
AABA
Altaba Inc
AABA
+$784M
2
ESRX
Express Scripts Holding Company
ESRX
+$504M
3
GD icon
General Dynamics
GD
+$348M
4
XL
XL Group Ltd.
XL
+$329M
5
KDP icon
Keurig Dr Pepper
KDP
+$194M

Top Sells

Rank Stock Value
1
NXPI icon
NXP Semiconductors
NXPI
+$618M
2
MON
Monsanto Co
MON
+$543M
3
COL
Rockwell Collins
COL
+$151M
4
ABLX
Ablynx NV
ABLX
+$134M
5
PPLI
People Inc
PPLI
+$112M

Sector Composition

Rank Sector Weight
1 Healthcare 19.63%
2 Technology 19.02%
3 Financials 14.39%
4 Communication Services 11.46%
5 Industrials 6.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
51
CRISPR Therapeutics
CRSP
$4.88B
$50.6M 0.31%
860,700
+215,700
+33% +$12.3M
NVCR icon
52
NovoCure
NVCR
$1.78B
$49.8M 0.31%
1,590,000
-260,000
-14% -$7.23M
EVHC
53
DELISTED
Envision Healthcare Holdings Inc
EVHC
$48M 0.3%
1,090,000
+725,000
+199% +$29.8M
CAVM
54
DELISTED
Cavium, Inc.
CAVM
$47.1M 0.29%
545,000
-1,345,000
-71% -$108M
ALNY icon
55
Alnylam Pharmaceuticals
ALNY
$29.5B
$40.9M 0.25%
415,000
+45,000
+12% +$4.46M
MRTX
56
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$36.7M 0.23%
743,500
+473,500
+175% +$17.9M
BUD icon
57
AB InBev
BUD
$166B
$36.1M 0.22%
+358,533
New +$35.6M
RC
58
Ready Capital
RC
$276M
$35.9M 0.22%
2,208,239
– –
HRG
59
DELISTED
HRG Group, Inc.
HRG
$30M 0.19%
2,290,000
-1,750,000
-43% -$23.4M
SVRA icon
60
Savara
SVRA
$1.09B
$25.2M 0.16%
2,225,000
– –
NTLA icon
61
Intellia Therapeutics
NTLA
$1.5B
$23M 0.14%
840,000
+190,000
+29% +$4.6M
DVAX
62
DELISTED
Dynavax Technologies
DVAX
$22M 0.14%
+1,440,000
New +$24.9M
PGNX
63
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$21.3M 0.13%
+2,651,100
New +$20.2M
BMS
64
DELISTED
Bemis
BMS
$18.7M 0.12%
442,500
-120,000
-21% -$5.18M
CDXS icon
65
Codexis
CDXS
$156M
$16.2M 0.1%
+1,125,000
New +$14.7M
CCXI
66
DELISTED
ChemoCentryx, Inc.
CCXI
$15.1M 0.09%
1,150,000
+200,000
+21% +$2.39M
VYGR icon
67
Voyager Therapeutics
VYGR
$181M
$15M 0.09%
768,157
-121,843
-14% -$2.41M
BLCM
68
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$14.8M 0.09%
+200,000
New +$15.6M
APTX
69
DELISTED
Aptinyx Inc. Common Stock
APTX
$14.4M 0.09%
+596,800
New +$12.8M
AMRN
70
Amarin Corp
AMRN
$297M
$13.9M 0.09%
224,250
-3,750
-2% -$232K
LRMR icon
71
Larimar Therapeutics
LRMR
$413M
$13M 0.08%
+105,545
New +$8.97M
GRFS
72
Grifois
GRFS
$5.35B
$11.9M 0.07%
551,304
+158,500
+40% +$3.46M
CHRS icon
73
Coherus Oncology
CHRS
$222M
$11.8M 0.07%
+845,000
New +$12.1M
SHPG
74
DELISTED
Shire pic
SHPG
$11.7M 0.07%
+69,547
New +$11.2M
ZEAL
75
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$11.4M 0.07%
900,000
+35,000
+4% +$532K
1 2
3
4 5

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Farallon Capital Management held 115 positions worth $16.2B, up 12% from $14.4B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Farallon Capital Management deployed $1.1B of net new capital in Q2 2018, opening 28 new positions and adding to 36 existing holdings. Its largest new stake was General Dynamics: 1,697,715 shares worth $316M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 15% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was NXP Semiconductors, an estimated $618M trimmed.

  • Farallon Capital Management's largest Q2 2018 buy was General Dynamics: 1,697,715 shares worth $316M.
  • Farallon Capital Management added most to Altaba Inc in Q2 2018, an estimated $784M increase.
  • Farallon Capital Management's biggest Q2 2018 reduction was NXP Semiconductors, cutting an estimated $618M.
  • Farallon Capital Management fully exited Monsanto Co in Q2 2018, selling an estimated $543M.
  • Farallon Capital Management's ten largest holdings make up 54% of its $16.2B portfolio in Q2 2018.
  • Farallon Capital Management opened 28 new positions and closed 20 in Q2 2018.
  • Farallon Capital Management's portfolio value rose 12% quarter-over-quarter to $16.2B.

Based on Farallon Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.